Ondansetron in Cats: Dosage Guidelines, Safety, and Side Effects

Ondansetron is a 5‑HT3 (serotonin) receptor antagonist used to control nausea and vomiting in cats. It can be administered as an injectable in‑hospital medication or as an oral tablet or solution for home use. Below you’ll find an overview of how it works, dosing considerations, administration tips, and safety information.

Quick Overview

• Medication type: 5‑HT3 (serotonin) receptor antagonist
• Form: Injectable, oral tablet (regular and disintegrating), oral solution
• Prescription required: Yes
• Life stage: No specific restriction
• Common brand name: Ondansetron
• Available dosages: 4 mg and 8 mg tablets; 0.8 mg/mL oral solution

How Ondansetron Works

5‑HT3 receptors are abundant in the gastrointestinal tract and the brain’s vomiting center. By blocking serotonin from binding to these receptors, ondansetron reduces both nausea (central effect) and vomiting (peripheral effect). It is often used alone or together with other anti‑emetics such as maropitant (Cerenia). Studies show that while Cerenia may stop vomiting more rapidly, ondansetron can be more effective at relieving the sensation of nausea.

Dosing Information for Cats

Ondansetron is used off‑label in veterinary medicine, so dosing is based on limited studies, clinical experience, and the individual cat’s needs. Typical dosing for a 10‑lb (4.5 kg) cat ranges from 2.5 mg to 4 mg, administered every 6–12 hours. Frequency and dose may be adjusted depending on the underlying cause (e.g., chemotherapy, dexmedetomidine‑induced nausea) and concurrent medications.

Administration Options

Oral tablets – Traditional tablets can be hidden in food, treats, or placed directly in the mouth. Disintegrating tablets dissolve on the tongue and are useful for cats that resist swallowing pills.

Oral solution – The 0.8 mg/mL solution requires larger volumes (e.g., a 2.5 mg dose needs 3 mL), which can be challenging for nauseous cats. Compounded formulations may be available from a pharmacy.

Injectable – Subcutaneous injection provides the highest bioavailability (≈75 % vs. ≈30 % for oral). Owners comfortable with sub‑Q injections (similar to insulin) can discuss this route with their veterinarian.

Transdermal – A study of a transdermal preparation failed to achieve therapeutic blood levels, so this route is not recommended.

Potential Side Effects

Ondansetron is generally well tolerated. Rare adverse effects may include:

• Constipation or mild diarrhea
• Sedation (possible due to serotonin blockade)
• Involuntary muscle movements (extrapyramidal signs)

Human data report rare liver enzyme elevation, cardiac arrhythmias, and low blood pressure, but these have not been documented in cats.

Overdose and Emergency Guidance

While the drug has a wide safety margin, toxicology data in cats are limited. In humans, doses up to ten times the recommended amount caused minimal illness. If you suspect an overdose, contact your veterinarian or a pet poison control hotline immediately:

• ASPCA Animal Poison Control Center: 1‑888‑426‑4435
• Pet Poison Helpline: 1‑855‑764‑7661

Drug Interactions to Consider

Concurrent use of certain drugs may increase the risk of serotonin syndrome or alter ondansetron metabolism. Discuss all medications with your vet. Notable interactions include:

• Azole antifungals (e.g., itraconazole) – may prolong QT interval
• Monoamine oxidase inhibitors (e.g., selegiline) – risk of serotonin syndrome
• Serotonergic drugs (fluoxetine, clomipramine, mirtazapine, trazodone, tramadol, methadone) – increased serotonin syndrome risk
• P‑glycoprotein inhibitors (cyclosporine) – higher ondansetron levels
• QT‑prolonging agents (cisapride) – potential arrhythmias
• Phenobarbital – may increase clearance of ondansetron

Storage Recommendations

Store oral tablets in a light‑resistant container at 68‑77 °F (20‑25 °C), with allowable excursions of 59‑86 °F (15‑30 °C). Disintegrating tablets should remain in the original foil blisters and be discarded after opening. Injectable solution should also be kept at 68‑77 °F, protected from light; discard if discoloration occurs. Some formulations may require refrigeration—always follow the product label.

References

1. A Budde, J., & A McCluskey, D. (2023). Ondansetron. In Plumb’s Veterinary Drug Handbook (10th ed.). Wiley Blackwell.
2. Baykurt, T. K., et al. (2025). Comparing the Antiemetic Effects of Maropitant and Ondansetron in Cats with Acute Vomiting. Journal of the Hellenic Veterinary Medical Society, 76(2), 9151–9162.
3. Batchelor, D. J., et al. (2013). Mechanisms, causes, investigation and management of vomiting disorders in cats: a literature review. Journal of Feline Medicine and Surgery, 15(4), 237–265.
4. Fitzpatrick, R. L., et al. (2015). Limited sampling pharmacokinetics of subcutaneous ondansetron in healthy geriatric cats, cats with chronic kidney disease, and cats with liver disease. Journal of Veterinary Pharmacology and Therapeutics, 39(4), 350–355.
5. Trepanier, L. (2010). Acute vomiting in cats. Journal of Feline Medicine and Surgery, 12(3), 225–230.
6. Santos, L. C. P., et al. (2011). A randomized, blinded, controlled trial of the antiemetic effect of ondansetron on dexmedetomidine‑induced emesis in cats. Veterinary Anaesthesia and Analgesia, 38(4), 320–327.
7. Quimby, J. M., et al. (2013). Oral, subcutaneous, and intravenous pharmacokinetics of ondansetron in healthy cats. Journal of Veterinary Pharmacology and Therapeutics, 37(4), 348–353.
8. Forsythe, L., & Gollakner, R. (n.d.). Ondansetron. VCA Animal Hospitals.
9. Zajic, L. B., et al. (2017). Assessment of absorption of transdermal ondansetron in normal research cats. Journal of Feline Medicine and Surgery, 19(12), 1245–1248.
10. Thompson, A., & Lummis, S. R. (2006). 5‑HT3 receptors. Current Pharmaceutical Design, 12(28), 3615–3630.